iCo Therapeutics Inc. (ICO.V)
| Previous Close | 0.0550 |
| Open | 0.0500 |
| Bid | 0.0650 x 0 |
| Ask | 0.0700 x 0 |
| Day's Range | 0.0500 - 0.0700 |
| 52 Week Range | 0.0200 - 0.0800 |
| Volume | 6,239,268 |
| Avg. Volume | 773,216 |
| Market Cap | 9.994M |
| Beta (5Y Monthly) | 2.70 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.0120 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- Newsfile
iCo Therapeutics Inc. Proposes to Re-Price Warrants
Vancouver, British Columbia--(Newsfile Corp. - January 11, 2021) - iCo Therapeutics Inc. (TSXV: ICO) (OTCQB: ICOTF) ("iCo" or the "Company"), announces that they are submitting an application to the TSX Venture Exchange to amend the exercise price of 66,200,000 previously granted common share purchase warrants (the "Warrants") issued pursuant to a private placement of 25,000,000 units that was completed over several tranches from January 31, 2019 to March 4, 2019 (the "Spring 2019 Private ...
- Newsfile
iCo Therapeutics Announces Joint Development of iCo-019 with Skymount Medical
Vancouver, British Columbia--(Newsfile Corp. - December 31, 2020) - iCo Therapeutics (TSXV: ICO) (OTCQB: ICOTF) ("iCo" or the "Company"), iCo Therapeutics, Inc. ("iCo") and Skymount Medical, Inc. ("Skymount") announced today that they have entered into a non-binding Memorandum of Understanding to develop iCo-019, iCo's oral Amphotericin B formulation. Skymount will initially commit up to $US 550,000 for pre-clinical work targeting the use of iCo-019 as a therapeutic product for infections relating to COVID-19."I ...
- Newsfile
iCo Therapeutics Announces Third Quarter 2020 Financial Results
Vancouver, British Columbia--(Newsfile Corp. - November 24, 2020) - Â iCo Therapeutics (TSXV: ICO) (OTCQB: ICOTF) ("iCo" or the "Company"), today reported financial results for the quarter ended September 30, 2020. Amounts, unless specified otherwise, are expressed in Canadian dollars and presented under International Financial Reporting Standards ("IFRS").Stated William Jarosz, CEO of iCo Therapeutics Inc., "We have aggressively continued to contain our operating expenses quarter over quarter and year over year. This has allowed ...
